Mutual of America Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Mutual of America Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-44,052	Closed	-$3.68M	–	1460
2024 Q4	$3.68M	Sell	44,052 -39	-0.1%	-$3.21K	0.04%	605
2024 Q3	$3.23M	Sell	44,091 -413	-0.9%	-$31K	0.03%	688
2024 Q2	$3.05M	Sell	44,504 -1,927	-4%	-$134K	0.03%	707
2024 Q1	$3.21M	Sell	46,431 -3,771	-8%	-$259K	0.03%	694
2023 Q4	$3.6M	Sell	50,202 -2,287	-4%	-$132K	0.04%	626
2023 Q3	$2.73M	Buy	52,489 +6,789	+15%	+$396K	0.03%	709
2023 Q2	$2.89M	Buy	45,700 +8,529	+23%	+$531K	0.03%	747
2023 Q1	$2.01M	Buy	+37,171	New	+$1.8M	0.02%	899
2022 Q4	–	Sell	-37,362	Closed	-$1.74M	–	1601
2022 Q3	$1.74M	Buy	+37,362	New	+$1.95M	0.02%	908

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Mutual of America Capital Management's ITCI Position: Q1 2025 in Review

Mutual of America Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 44,052 shares — an estimated $3.68M sold.

Mutual of America Capital Management first reported a position in ITCI in Q3 2022 and held it in 9 quarters. The position peaked at $3.68M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Mutual of America Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Mutual of America Capital Management sold 44,052 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $3.68M.
Mutual of America Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 9 quarters.
Mutual of America Capital Management's Intra-Cellular Therapies Inc. position peaked at $3.68M in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Mutual of America Capital Management's 13F filing for Q1 2025, filed 1 May 2025.